GetTopicDetailResponse(id=3921122e256, topicName=MSC2156119J, introduction=MSC2156119J, content=null, image=null, comments=4, allHits=1180, url=https://h5.medsci.cn/topic?id=12272, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=28805, tagList=[TagDto(tagId=28805, tagName=MSC2156119J)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1675419, encodeId=2aa416e541917, content=<a href='/topic/show?id=3921122e256' target=_blank style='color:#2F92EE;'>#MSC2156119J#</a>, objectTitle=招募患者：比較MSC2156119J聯(lián)合吉非替尼與化療治療EGFR突變的MET陽性晚期NSCLC患者的Ib及II期臨床試驗, objectType=article, longId=56022, objectId=21385602249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21385602249, replyNumber=0, likeNumber=71, createdTime=2016-04-23, rootId=0, userName=FukaiBao, userId=927e27222171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21385602249, moduleTitle=招募患者：比較MSC2156119J聯(lián)合吉非替尼與化療治療EGFR突變的MET陽性晚期NSCLC患者的Ib及II期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=21385602249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675418, encodeId=05ef16e54185b, content=<a href='/topic/show?id=3921122e256' target=_blank style='color:#2F92EE;'>#MSC2156119J#</a>, objectTitle=招募患者：MSC2156119J對比索拉非尼治療晚期肝細胞癌受試者的有效性、安全性和PK的多中心、隨機、Ib聯(lián)合II期臨床試驗, objectType=article, longId=56011, objectId=342c560114a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=342c560114a, replyNumber=0, likeNumber=90, createdTime=2016-07-28, rootId=0, userName=FukaiBao, userId=927e27222171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=342c560114a, moduleTitle=招募患者：MSC2156119J對比索拉非尼治療晚期肝細胞癌受試者的有效性、安全性和PK的多中心、隨機、Ib聯(lián)合II期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=342c560114a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675417, encodeId=fdfe16e541779, content=<a href='/topic/show?id=3921122e256' target=_blank style='color:#2F92EE;'>#MSC2156119J#</a>, objectTitle=ASCO 2014：MSC2156119J+吉非替尼治療MET陽性EGFR突變晚期NSCLC的I/II期臨床試驗, objectType=article, longId=35667, objectId=f1cf3566e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1cf3566e12, replyNumber=0, likeNumber=81, createdTime=2015-04-01, rootId=0, userName=FukaiBao, userId=927e27222171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1cf3566e12, moduleTitle=ASCO 2014：MSC2156119J+吉非替尼治療MET陽性EGFR突變晚期NSCLC的I/II期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f1cf3566e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675416, encodeId=80b516e5416d4, content=<a href='/topic/show?id=3921122e256' target=_blank style='color:#2F92EE;'>#MSC2156119J#</a>, objectTitle=ASCO 2014：亞洲進展期肝癌患者口服c-Met抑制劑MSC2156119J單藥與索拉非尼比較的Ib/II期試驗, objectType=article, longId=35648, objectId=35c7356487a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c7356487a, replyNumber=0, likeNumber=81, createdTime=2014-06-23, rootId=0, userName=FukaiBao, userId=927e27222171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c7356487a, moduleTitle=ASCO 2014：亞洲進展期肝癌患者口服c-Met抑制劑MSC2156119J單藥與索拉非尼比較的Ib/II期試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=35c7356487a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
